Castle Biosciences Share Price (NASDAQ: CSTL)

$20.53

▲

0.56

(2.8%)

Live

Last updated on August 23, 2025 at 12:35 AM IST

$₹

Check the interactive Castle Biosciences Stock chart to analyse performance

Castle Biosciences stock performance

as on August 23, 2025 at 12:35 AM IST

Today's Low:$20.53
Today's High:$20.60
$20.53
0.0%
Downside
Day's Volatility :0.34%
Upside
0.34%
52 Weeks Low:$14.59
52 Weeks High:$35.84
$20.53
28.93%
Downside
52 Weeks Volatility :59.29%
Upside
42.72%

Castle Biosciences Stock Returns

Period	Castle Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	23.91%	5.0%	0.0%
6 Months	-22.52%	-6.4%	0.0%
1 Year	-27.53%	-11.5%	0.0%
3 Years	-35.62%	4.5%	-7.7%

Castle Biosciences Inc Key Stats

Check Castle Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$19.97
Open	$19.97
Today's High	$20.99
Today's Low	$20.57
Market Capitalization	$579.3M
Today's Volume	$227.3K
52 Week High	$35.84
52 Week Low	$14.59
Revenue TTM	$346.3M
EBITDA	$19.4M
Earnings Per Share (EPS)	$-0.34
Profit Margin	-2.73%
Quarterly Earnings Growth YOY	-0.52%
Return On Equity TTM	-2.15%

Stock Returns calculator for Castle Biosciences Stock including INR - Dollar returns

The Castle Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Castle Biosciences investment value today

Current value as on today

₹78,828

Returns

₹21,172

(-21.17%)

Returns from Castle Biosciences Stock

₹25,427 (-25.43%)

Dollar Returns*

₹4,255 (+4.25%)

Indian investors sentiment towards Castle Biosciences Stock

550%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Search interest for Castle Biosciences Stock from India on INDmoney has increased by 550% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Castle Biosciences Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
10.29%
Vanguard Group Inc
7.48%
Principal Financial Group Inc
6.20%
Dimensional Fund Advisors, Inc.
4.75%
Portolan Capital Management, LLC
4.36%
Wasatch Advisors LP
3.44%

Analyst Recommendation on Castle Biosciences Stock

Rating

Trend

Buy

93%Buy

6%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Castle Biosciences(by analysts ranked 0 to 5 stars)

Castle Biosciences Share Price Target

What analysts predicted

Upside of 73.53%

Target:

$35.63

Current:

$20.53

Castle Biosciences share price target is $35.63, a slight Upside of 73.53% compared to current price of $20.53 as per analysts' prediction.

Castle Biosciences Stock Insights

Price Movement
In the last 1 month, CSTL stock has moved up by 22.2%
Decreasing Revenue
Revenue is down for the last 2 quarters, 87.98M → 86.18M (in $), with an average decrease of 2.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -25.84M → 4.52M (in $), with an average increase of 671.5% per quarter
CSTL vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 28.7% return, outperforming this stock by 56.2%
CSTL vs IDXX (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has given 76.5% return, outperforming this stock by 112.6%
Price to Sales
ForCSTL every $1 of sales, investors are willing to pay $1.6, whereas for Idexx Laboratories, Inc., the investors are paying $12.8 for every $1 of sales.

Castle Biosciences Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$51.9M	↑ 127.62%
Net Income	$5.3M	↓ 182.88%
Net Profit Margin	10.17%	↑ 38.11%

	FY20	Y/Y Change
Revenue	$62.6M	↑ 20.79%
Net Income	$-10.3M	↓ 294.88%
Net Profit Margin	-16.42%	↓ 26.59%

	FY21	Y/Y Change
Revenue	$94.1M	↑ 50.18%
Net Income	$-31.3M	↑ 204.28%
Net Profit Margin	-33.26%	↓ 16.84%

	FY22	Y/Y Change
Revenue	$137.0M	↑ 45.65%
Net Income	$-67.1M	↑ 114.55%
Net Profit Margin	-48.99%	↓ 15.73%

	FY23	Y/Y Change
Revenue	$219.8M	↑ 60.38%
Net Income	$-57.5M	↓ 14.41%
Net Profit Margin	-26.15%	↑ 22.84%

	FY24	Y/Y Change
Revenue	$332.1M	↑ 51.09%
Net Income	$18.2M	↓ 131.75%
Net Profit Margin	5.49%	↑ 31.64%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$73.0M	↑ 10.37%
Net Income	$-2.5M	↓ 1.78%
Net Profit Margin	-3.47%	↑ 0.43%

	Q2 FY24	Q/Q Change
Revenue	$87.0M	↑ 19.22%
Net Income	$8.9M	↓ 452.01%
Net Profit Margin	10.25%	↑ 13.72%

	Q3 FY24	Q/Q Change
Revenue	$85.8M	↓ 1.4%
Net Income	$2.3M	↓ 74.56%
Net Profit Margin	2.65%	↓ 7.6%

	Q4 FY24	Q/Q Change
Revenue	$86.3M	↑ 0.62%
Net Income	$9.6M	↑ 322.65%
Net Profit Margin	11.11%	↑ 8.46%

	Q1 FY25	Q/Q Change
Revenue	$88.0M	↑ 1.94%
Net Income	$-25.8M	↓ 369.53%
Net Profit Margin	-29.38%	↓ 40.49%

	Q2 FY25	Q/Q Change
Revenue	$86.2M	↓ 2.05%
Net Income	$4.5M	↓ 117.5%
Net Profit Margin	5.25%	↑ 34.63%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$44.6M	↑ 154.76%

	FY20	Y/Y Change
Profit	$53.0M	↑ 18.87%

	FY21	Y/Y Change
Profit	$78.3M	↑ 47.77%

	FY22	Y/Y Change
Profit	$105.0M	↑ 34.2%

	FY23	Y/Y Change
Profit	$174.8M	↑ 66.43%

	FY24	Y/Y Change
Profit	$271.9M	↑ 55.52%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$56.4M	↑ 10.52%

	Q2 FY24	Q/Q Change
Profit	$69.8M	↑ 23.72%

	Q3 FY24	Q/Q Change
Profit	$70.2M	↑ 0.57%

	Q4 FY24	Q/Q Change
Profit	$70.1M	↓ 0.06%

	Q1 FY25	Q/Q Change
Profit	$71.6M	↑ 2.11%

	Q2 FY25	Q/Q Change
Profit	$66.1M	↓ 7.75%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$7.0M	↓ 157.06%
Investing Cash Flow	$-937.0K	↑ 238.22%
Financing Cash Flow	$88.3M	↑ 457.44%

	FY20	Y/Y Change
Operating Cash Flow	$9.9M	↑ 40.63%
Investing Cash Flow	$-4.7M	↑ 406.72%
Financing Cash Flow	$305.9M	↑ 246.47%

	FY21	Y/Y Change
Operating Cash Flow	$-19.0M	↓ 292.43%
Investing Cash Flow	$-66.7M	↑ 1303.9%
Financing Cash Flow	$5.4M	↓ 98.23%

	FY22	Y/Y Change
Operating Cash Flow	$-41.7M	↑ 119.43%
Investing Cash Flow	$-166.5M	↑ 149.85%
Financing Cash Flow	$1.5M	↓ 72.05%

	FY23	Y/Y Change
Operating Cash Flow	$-5.6M	↓ 86.49%
Investing Cash Flow	$-16.2M	↓ 90.28%
Financing Cash Flow	$-2.3M	↓ 251.68%

	FY24	Y/Y Change
Operating Cash Flow	$64.9M	↓ 1252.97%
Investing Cash Flow	$-50.1M	↑ 209.81%
Financing Cash Flow	$6.1M	↓ 367.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-6.8M	↓ 128.39%
Investing Cash Flow	$-19.7M	↑ 156.79%
Financing Cash Flow	$10.6M	↓ 422.84%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$24.0M	↓ 451.1%
Investing Cash Flow	$-21.4M	↑ 8.71%
Financing Cash Flow	$42.0K	↓ 99.61%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$23.3M	↓ 2.75%
Investing Cash Flow	$-14.8M	↓ 30.95%
Financing Cash Flow	$838.0K	↑ 1895.24%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$24.4M	↑ 4.4%
Investing Cash Flow	$5.8M	↓ 139.02%
Financing Cash Flow	$-5.4M	↓ 742.6%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-6.0M	↓ 124.77%
Investing Cash Flow	$-22.4M	↓ 488.75%
Financing Cash Flow	$-1.6M	↓ 71.16%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$20.8M	↓ 444.95%
Investing Cash Flow	$-28.4M	↑ 26.51%
Financing Cash Flow	$101.0K	↓ 106.5%

Castle Biosciences Technicals Summary

Sell

Neutral

Buy

Castle Biosciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Castle Biosciences Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Castle Biosciences Inc	18.75%	-22.52%	-27.53%	-35.62%	-56.24%
Agilent Technologies Inc.	-1.93%	-13.44%	-16.44%	-11.66%	20.05%
Idexx Laboratories, Inc.	17.02%	39.74%	28.67%	77.27%	66.23%
Thermo Fisher Scientific, Inc.	3.61%	-9.2%	-19.92%	-15.6%	15.2%
Danaher Corp.	3.11%	-2.94%	-23.81%	-28.16%	-0.73%
Iqvia Holdings Inc.	-4.59%	-2.99%	-24.35%	-19.16%	18.61%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Castle Biosciences Inc	31.21	NA	NA	-1.56	-0.02	-0.03	NA	15.71
Agilent Technologies Inc.	28.85	28.85	1.75	5.58	0.19	0.08	0.01	21.61
Idexx Laboratories, Inc.	52.62	52.62	4.79	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.01	28.01	2.02	22.49	0.13	0.05	0.0	133.77
Danaher Corp.	44.88	44.88	2.12	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	26.91	26.91	1.1	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Castle Biosciences Inc	Buy	$579.3M	-56.24%	31.21	-2.73%
Agilent Technologies Inc.	Buy	$33.3B	20.05%	28.85	17.59%
Idexx Laboratories, Inc.	Buy	$50.6B	66.23%	52.62	24.41%
Thermo Fisher Scientific, Inc.	Buy	$182.7B	15.2%	28.01	15.24%
Danaher Corp.	Buy	$151.4B	-0.73%	44.88	14.21%
Iqvia Holdings Inc.	Buy	$31.5B	18.61%	26.91	7.88%

About Castle Biosciences Inc

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Organization	Castle Biosciences
Employees	798
CEO	Mr. Derek J. Maetzold
Industry	Health Technology

Key Management of Castle Biosciences Inc

Name	Title
Mr. Derek J. Maetzold	Founder, CEO, President & Director
Mr. Frank Stokes	CFO & Treasurer
Ms. Kristen M. Oelschlager R.N.	Chief Operating Officer
Mr. Tobin W. Juvenal	Chief Commercial Officer
Ms. Camilla Zuckero	Vice President of Investor Relations & Corporate Affairs
Mr. Kevin Doman	Vice President of Sales
Dr. Jay Braxton Pharm.D.	VP of Marketing & Brand Manager of Uveal Melanoma (UM)
Ms. Keli Greenberg	Vice President of Human Resources
Dr. Matthew Goldberg M.D.	Senior Vice President of Medical

Important FAQs about investing in CSTL Stock from India :

What is Castle Biosciences share price today?

Castle Biosciences share price today is $20.53 as on August 23, 2025 at 12:35 AM IST. Castle Biosciences share today touched a day high of $20.60 and a low of $20.53.

What is the 52 week high and 52 week low for Castle Biosciences share?

Castle Biosciences share touched a 52 week high of $35.84 and a 52 week low of $14.59. Castle Biosciences stock price today i.e. August 23, 2025 at 12:35 AM IST is trending at $20.53, lower by 42.72% versus the 52 week high.

How to invest in Castle Biosciences Stock (CSTL) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Castle Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Castle Biosciences Shares that will get you 0.0731 shares as per Castle Biosciences share price of $20.53 per share as on August 23, 2025 at 12:35 AM IST.

What is the minimum amount required to buy Castle Biosciences Stock (CSTL) from India?

Indian investors can start investing in Castle Biosciences (CSTL) shares with as little as ₹87.499 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.99 in Castle Biosciences stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Castle Biosciences share’s latest price of $20.53 as on August 23, 2025 at 12:35 AM IST, you will get 0.4871 shares of Castle Biosciences. Learn more about fractional shares .

What are the returns that Castle Biosciences has given to Indian investors in the last 5 years?

Castle Biosciences stock has given -56.24% share price returns and 17.97% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?